-

05:05:33 PM

LIVE Real Time PTCT Stock Market News

PTCT - PTC Therapeutics Inc

05/04/21 4:01 PM

Nasdaq : PTCT

PTC Therapeutics Provides a Corporate Update and Reports First Quarter 2021 Financial Results

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ending March 31, 2021. "Overall PTC has had a strong performance this quarter through all aspects of the company from discovery to

RHEA-AI

neutral

04/27/21 8:00 AM

Nasdaq : PTCT

PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences:BofA Securities 2021 Virtual Health Care Conference Tuesday, May 11 th at 8:45 a.m. ET2021 RBC Capital Markets

RHEA-AI

neutral

04/20/21 8:00 AM

Nasdaq : PTCT

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2021 Financial Results

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2021 financial results and provide an update on the company's business and outlook on Tuesday, May 4, 2021 at

RHEA-AI

neutral

04/19/21 4:30 PM

Nasdaq : PTCT

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 13, 2021 it approved non-statutory stock options to purchase an aggregate of 75,085 shares of its common stock and 33,740 restricted stock units ("RSUs"), each representing the

RHEA-AI

neutral

04/15/21 1:00 AM

Nasdaq : PTCT

Continued Improvements in Motor Milestones in Infants with Type 1 Spinal Muscular Atrophy After Two Years of Treatment with Evrysdi(TM)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that results from Part 2 of the pivotal FIREFISH trial demonstrated that infants with type 1 spinal muscular atrophy (SMA) treated with Evrysdi(TM) (risdiplam) obtained increases in survival

RHEA-AI

neutral

04/14/21 8:00 AM

Nasdaq : PTCT

PTC Therapeutics Launches the PTC Pinpoint Direct(TM) Program for Patient-Initiated Genetic Testing

PTC Therapeutics, Inc. (NASDAQ: PTCT) today introduced a new no-charge, patient-initiated testing program in the United States for individuals who have symptoms consistent with, or a diagnosis of, cerebral palsy (CP) with no evidence of brain

RHEA-AI

neutral

04/07/21 9:30 AM

Nasdaq : PTCT

PTC Therapeutics Received Gallup's "Don Clifton Strengths-Based Culture" Award

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has been named a winner of the 2021 "Don Clifton Strengths-Based Culture Award" from Gallup. The award recognizes organizations with strong workplace cultures that get the best out of

RHEA-AI

neutral

04/07/21 8:50 AM

Nasdaq : PTCT

PTC Therapeutics to Host PTC518 Huntington Disease Deep Dive Webinar

PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webinar in its deep dive series discussing the PTC518 Huntington disease (HD) program on Thursday, April 15 at 9 a.m. E.T.The Huntington Disease Deep Dive will provide an overview of PTC's

RHEA-AI

neutral

04/01/21 8:00 AM

Nasdaq : PTCT

PTC Therapeutics Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi(TM)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that a $20 million milestone payment was triggered by the first commercial sale of Evrysdi (TM) (risdiplam) in the European Union under its License and Collaboration Agreement with Roche.

RHEA-AI

very positive

03/30/21 1:00 AM

Nasdaq : PTCT

PTC Therapeutics Announces the European Approval of Evrysdi(TM) for the Treatment of Spinal Muscular Atrophy

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the European Commission (EC) has granted marketing authorization to Evrysdi(TM) (risdiplam) for the treatment of spinal muscular atrophy (SMA) in patients 2 months and older. Evrysdi will

RHEA-AI

very positive

1 2 3 4 5 6 Next